简化IVIM模型扩散MRI在放化疗期间预测IDH野生型胶质母细胞瘤治疗反应
本研究纳入38例新诊断IDH野生型胶质母细胞瘤患者,在放化疗基线、第10次和第20次分次时行标准化MRI,采用简化IVIM模型生成ADC和灌注分数图。结果显示基线ADCT2-FLAIR较高、第10次分次fT2-FLAIR较低及第20次分次ADCT2-FLAIR较基线无升高与早期进展相关,联合临床因素可提高预测AUC至90.3%。
要点
- 基线ADCT2-FLAIR较高与早期进展相关(OR=1.06)。
- 第10次分次fT2-FLAIR较低与早期进展相关(OR=2.11)。
- 第20次分次ADCT2-FLAIR较基线无升高与早期进展相关(OR=1.12)。
核心结论
- 基线ADCT2-FLAIR、第20次分次ADCT2-FLAIR较基线无升高或第10次分次fT2-FLAIR显著预测早期进展。
- 第10次分次fT2-FLAIR与更长的无进展生存期相关。
研究设计与样本
- 38例新诊断IDH野生型胶质母细胞瘤患者接受6周/30次放化疗。
- 在基线(放疗计划)、第10次和第20次分次时行标准化术后MRI。
- 独立分割非重叠T1增强区和T2-FLAIR高信号区,用简化IVIM模型生成ADC和灌注分数图。
主要发现
- 基线ADCT2-FLAIR较高与早期进展相关(OR=1.06,95%CI 1.01-1.15,p=0.025)。
- 第10次分次fT2-FLAIR较低与早期进展相关(OR=2.11,95%CI 1.04-4.27,p=0.018)。
- 第20次分次ADCT2-FLAIR较基线无升高与早期进展相关(OR=1.12,95%CI 1.02-1.22,p=0.02)。
- 联合基线ADCT2-FLAIR、第10次分次fT2-FLAIR、ECOG和MGMT启动子甲基化状态将AUC提高至90.3%(p=0.001)。
- 多变量分析中IVIM指标均与总生存期无关,但第10次分次fT2-FLAIR较高与更长无进展生存期相关(HR=0.72,95%CI 0.56-0.95,p=0.018)。
临床怎么用
- 放化疗期间简化IVIM MRI指标可用于辅助预测IDH野生型胶质母细胞瘤早期进展。
- 联合基线ADCT2-FLAIR、第10次分次fT2-FLAIR、ECOG和MGMT状态可提高预测性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prediction of early progression in glioblastoma may provide an opportunity to personalize treatment. Simplified intravoxel incoherent motion (IVIM) MRI offers quantitative estimates of diffusion and perfusion metrics. We investigated whether these metrics, during chemoradiation, could predict treatment outcome. METHODS: 38 patients with newly diagnosed IDH-wildtype glioblastoma undergoing 6-week/30-fraction chemoradiation had standardized post-operative MRIs at baseline (radiation planning), and at the 10th and 20th fractions. Non-overlapping T1-enhancing (T1C) and non-enhancing T2-FLAIR hyperintense regions were independently segmented. Apparent diffusion coefficient (ADCT1C, ADCT2-FLAIR) and perfusion fraction (fT1C, fT2-FLAIR) maps were generated with simplified IVIM modelling. Parameters associated with progression before or after 6.9 months (early vs late progression, respectively), overall survival (OS) and progression-free survival (PFS) were investigated. RESULTS: Higher ADCT2-FLAIR at baseline [Odds Ratio (OR) = 1.06, 95% CI 1.01-1.15, p = 0.025], lower fT2-FLAIR at fraction 10 (OR = 2.11, 95% CI 1.04-4.27, p = 0.018), and lack of increase in ADCT2-FLAIR at fraction 20 compared to baseline (OR = 1.12, 95% CI 1.02-1.22, p = 0.02) were associated with early progression. Combining ADCT2-FLAIR at baseline, fT2-FLAIR at fraction 10, ECOG and MGMT promoter methylation status significantly improved AUC to 90.3% compared to a model with only ECOG and MGMT promoter methylation status (p = 0.001). Using multivariable analysis, neither IVIM metrics were associated with OS but higher fT2-FLAIR at fraction 10 (HR = 0.72, 95% CI 0.56-0.95, p = 0.018) was associated with longer PFS. CONCLUSION: ADCT2-FLAIR at baseline, its lack of increase from baseline to fraction 20, or fT2-FLAIR at fraction 10 significantly predicted early progression. fT2-FLAIR at fraction 10 was associated with PFS.
引用
- Jabehdar Maralani P, Myrehaug S, Mehrabian H, et al. Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma. Radiother Oncol. 2021. PMID: 33418005. doi:10.1016/j.radonc.2020.12.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。